Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.
Overview
- Legorreta Cancer Center of Brown University, Providence, RI 02903, USA
- Division of Hematology and Oncology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
- Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
- Division of Rheumatology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
- Department of Neurosurgery, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
Abstract
The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Code and data availability statement
The paper has a code and data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:
- it says that the data are available on request
- it says that the code is available on request
Read it in the paper: doi.org/10.1016/j.omton.2026.201201.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 11 keywords, 4 funders, 56 references.
Cite
This paper
Choi, M. J., So, E. Y., Akosman, B., Lee, Y. E., Raufi, A. G., Reginato, A. M., Chen, C. C., Lawler, S. E., Wong, E. T., & Liang, O. D. (2026). Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. Molecular therapy. Oncology, 34(2), 201201. https://
BibTeX
@article{choi2026enable,
author = {Choi, Moon Jung and So, Eui Young and Akosman, Bedia and Lee, Young Eun and Raufi, Alexander G and Reginato, Anthony M and Chen, Clark C and Lawler, Sean E and Wong, Eric T and Liang, Olin D},
title = {{Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager}},
journal = {Molecular therapy. Oncology},
year = {2026},
month = apr,
volume = {34},
number = {2},
pages = {201201},
publisher = {American Society of Gene \& Cell Therapy},
issn = {2950-3299},
doi = {10.1016/
url = {https://
pmid = {42094336},
pmcid = {PMC13141506}
}
RIS
TY - JOUR
AU - Choi, Moon Jung
AU - So, Eui Young
AU - Akosman, Bedia
AU - Lee, Young Eun
AU - Raufi, Alexander G
AU - Reginato, Anthony M
AU - Chen, Clark C
AU - Lawler, Sean E
AU - Wong, Eric T
AU - Liang, Olin D
TI - Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager
T2 - Molecular therapy. Oncology
J2 - Mol Ther Oncol
PY - 2026
DA - 2026/
VL - 34
IS - 2
SP - 201201
SN - 2950-3299
PB - American Society of Gene & Cell Therapy
DO - 10.1016/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1016/
"type": "article-journal",
"title": "Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager",
"container-title": "Molecular therapy. Oncology",
"author": [
{
"family": "Choi",
"given": "Moon Jung"
},
{
"family": "So",
"given": "Eui Young"
},
{
"family": "Akosman",
"given": "Bedia"
},
{
"family": "Lee",
"given": "Young Eun"
},
{
"family": "Raufi",
"given": "Alexander G"
},
{
"family": "Reginato",
"given": "Anthony M"
},
{
"family": "Chen",
"given": "Clark C"
},
{
"family": "Lawler",
"given": "Sean E"
},
{
"family": "Wong",
"given": "Eric T"
},
{
"family": "Liang",
"given": "Olin D"
}
],
"container-title-short":
"volume": "34",
"issue": "2",
"page": "201201",
"DOI": "10.1016/
"PMID": "42094336",
"PMCID": "PMC13141506",
"ISSN": "2950-3299",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
8
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.cell.2026.05.026 [code]
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Journal: CellIn common: other condition, 8 references
- [2] doi:10.3389/fimmu.2021.721830
- Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Journal: Frontiers in immunologyIn common: other condition, 7 references
- [3] doi:10.1016/j.omto.2022.07.006
- Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.Journal: Molecular therapy oncolyticsIn common: other condition, cellular / molecular, 6 references
- [4] doi:10.1136/jitc-2024-009574 [code]
- Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma.Journal: Journal for immunotherapy of cancerIn common: other condition, cellular / molecular, 5 references
- [5] doi:10.3390/ijms24032111
- Natural Killer Cell-Based Immunotherapy against Glioblastoma.Journal: International journal of molecular sciencesIn common: other condition, cellular / molecular, 5 references
- [6] doi:10.1016/j.celrep.2025.116099 [code]
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas.Journal: Cell reportsIn common: other condition, cellular / molecular, 4 references
- [7] doi:10.1016/j.xcrm.2026.102967 [code]
- Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.Journal: Cell reports. MedicineIn common: other condition, 4 references
- [8] doi:10.1038/s41586-026-10641-1 [code]
- Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.Journal: NatureIn common: other condition, cellular / molecular, 4 references
- [9] doi:10.1038/s41591-024-03152-x
- Cranioencephalic functional lymphoid units in glioblastoma.Journal: Nature medicineIn common: other condition, 4 references
- [10] doi:10.1038/s41540-025-00642-7 [code]
- Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment.Journal: NPJ systems biology and applicationsIn common: other condition, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
